论文部分内容阅读
目的观察尿激酶联合低分子肝素治疗急性心肌梗死的临床疗效。方法将我科收治的符合急性心肌梗死溶栓标准的95例患者随机分为对照组和观察组,其中对照组47例,给予尿激酶150万U加入100ml生理盐水内行溶栓治疗,于半小时内静脉滴注完毕;观察组48例,在对照组的基础上,于溶栓前加用低分子肝素钙5000IU静脉推注进行治疗,比较两组的临床疗效。结果对照组治疗后冠状动脉血管再通率为91.7%,观察组再通率为68.1%,差异有统计学意义(P<0.05);观察组死亡率为2.1%,对照组为14.9%,差异有统计学意义(P<0.05)。结论尿激酶联合低分子肝素治疗急性心肌梗死显著疗效显著,且预后好,值得广泛应用。
Objective To observe the clinical efficacy of urokinase combined with low molecular weight heparin in the treatment of acute myocardial infarction. Methods A total of 95 patients with acute myocardial infarction in our department were randomly divided into control group and observation group. 47 cases in control group were given 1.5 million Urokinase plus 100 ml normal saline for thrombolytic therapy at half an hour Intravenous instillation was completed; the observation group of 48 cases, on the basis of the control group, before the thrombolysis plus low molecular weight heparin 5000IU intravenous bolus treatment, the clinical efficacy of the two groups were compared. Results The rate of coronary recanalization in the control group was 91.7% and the recanalization rate in the observation group was 68.1% (P <0.05). The mortality rate in the observation group was 2.1% and that in the control group was 14.9% There was statistical significance (P <0.05). Conclusion The combination of urokinase and low molecular weight heparin has significant curative effect on acute myocardial infarction and its prognosis is good. It is worth to be widely used.